Navigation Links
Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
Date:9/3/2013

t of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, revolutionizing the treatment of diabetes with our products, and ORMD-0901 being a more patient-friendly form of treatment or it addressing a significant market. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
2. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
3. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
4. Oramed Pharmaceuticals Announces Reverse Stock Split
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. Marrone Bio Innovations Submits New Bioherbicide for EPA Registration
7. Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union
8. iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
9. WellnessFX Launches New Products e-HealthAnswers and Womens Fertility Package
10. XY Precision Positioning Stage Provides Nanometer Incremental Motion in a Small Package: PI introduces Affordable 2-Axis Piezo Positioner, Model P-763
11. FDA/PhUSE Collaboration: Study Data Reviewer’s Guide Work Package v1.1 Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... 30, 2014 Grace Century portfolio project, ... Manganello, Chairman of the Board, to the National Stem ... appointment was made by the Ministry of Health on behalf ... , More than a year after Bahamian Parliament ... Prime Minister Perry Christie said the government has completed the ...
(Date:10/30/2014)... severe flooding that devastated a wide swath of Colorado ... bridges, roads and other infrastructure had been upgraded or ... of Colorado Denver. , "People need to understand the ... associate professor of structural engineering at the CU Denver ... the study. "There is an assumption that a bridge ...
(Date:10/27/2014)... -- Kalorama Information says that PCR is demonstrating its ... the United States and is the dominant ... the FDA,s Emergency Use Authorization (EUA) to authorize the emergency ... of the Ebola virus was an indication that the ... IVD industry and its biennial survey on diagnostics markets ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... Danaher Corporation (NYSE:,DHR) announced that Executive Vice President ... presenting at the Robert W. Baird Industrial,Conference in ... 1:55 p.m. CST.,The audio will be simultaneously webcast ... a leading manufacturer of Professional,Instrumentation, Medical Technologies, Industrial ...
... ) reports third quarter 2008 results for the period,ended September 30, ... -- Sales increased 3.2% (-1.7% excluding foreign currency) compared to ... the quarter was up $1.7 million to $11.4 million ... of cash was $92.0 million at the end of third quarter ...
... Company,(Nasdaq: PRGO ; TASE) today announced that its ... share, payable on December 16, 2008 to,shareholders of record ... per share represents a ten percent increase over $0.05 ... Company is a leading global healthcare supplier that develops,manufactures ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:10/27/2014)... CA – October 28, 2014 – A new randomized ... proprietary blend of collagen and calcium, KoACT®, was far ... the leaching of calcium from bones and rebuilding new ... PubMed at: http://www.ncbi.nlm.nih.gov/pubmed/25314004 , ahead of print in ... The research was conducted by Bahram H. Arjmandi, PhD, ...
(Date:10/27/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market issues a ... Chief Technology Officer. Mr Tunnell examines the case for ... the variety of new payment solutions being released, consumers ... has its own attributes that promise to make payments ...
(Date:10/27/2014)... results from a safety and immunogenicity study, which ... that a live attenuated enterotoxigenic Escherichia coli ... a novel adjuvant, provided significant protection against disease. ... vaccine/adjuvant combination, which was 58.5 percent efficacious in ... highly rigorous ETEC human challenge model. The vaccine/adjuvant ...
Breaking Biology News(10 mins):New RCT: KoACT® beats calcium and vitamin D for optimal bone strength 2Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 2Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 3Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 4Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea 2
... The University of Manchester have made a surprising finding ... have big implications for research into human healing and ... salamanders have remarkable regenerative capacities, in contrast to mammals, ... tail a new one will regenerate within a week. ...
... Fujian and Shenzhen, China- An international research consortium, led ... completed the first genome sequence of the diamondback moth ... crops. This work provides wider insights into insect adaptation ... sustainable pest management. The latest study was published online ...
... release is available in French and German ... Royal Veterinary College London. Scientists have been able to ... the backbone of early tetrapods, the earliest four-legged animals. High-energy ... to reconstruct the backbones of the 360 million year old ...
Cached Biology News:The secrets of a tadpole's tail and the implications for human healing 2The secrets of a tadpole's tail and the implications for human healing 3The genome of diamondback moth provides new clues for sustainable pest management 2The genome of diamondback moth provides new clues for sustainable pest management 3Scientists reassemble the backbone of life with a particle acceleratorynchrotron X-rays 2Scientists reassemble the backbone of life with a particle acceleratorynchrotron X-rays 3
... The Vibratome Company has joined forces with ... the Vibratome 411301 Tissue Chopper. This tissue ... sections of tissue for metabolic experiments and ... irregular specimens available at biopsy or from ...
... The Vibratome Company has joined forces ... introduce the Vibratome 800 Tissue Chopper. This ... prepare sections of tissue for metabolic experiments ... and irregular specimens available at biopsy or ...
... design, The Bioactive peptides are molecules of ... biological behaviour or activity which can be ... diagnostic, chemical and agro-food applications. In this ... peptides with superior properties for therapeutic applications. ...
... within neurons in vesicles called synaptosomes. ... synaptic bouton. Synaptosomes may be ... other cellular debris. Abnormalites in neurotransmitter ... pathological condtions. Conditions of release ...
Biology Products: